Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Featured Studies Results
Cancer: Breast | Study Type: Treatment
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
Clinicaltrials.gov identifier:
NCT05169437
Treatment
Any advanced or metastatic solid tumor except ovarian or prostate
Testing a Targeted Therapy in Combination with Chemotherapy for Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT04491942
Treatment
Treatment study for people with advanced cancers
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Immunotherapy and PARP Inhibitor for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with a BRCA Mutation
Clinicaltrials.gov identifier:
NCT04673448
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05252390
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04584255
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
Clinicaltrials.gov identifier:
NCT04644068
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)
Clinicaltrials.gov identifier:
NCT04497116
Treatment
Advanced solid tumors
Screening for Cancer DNA in the Blood after Treatment for Early-Stage TNBC and/or a BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)
Clinicaltrials.gov identifier:
NCT04915755
Treatment
Early-stage TNBC or early-stage breast cancer with a BRCA mutation
ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer
Clinicaltrials.gov identifier:
NCT04267939
Treatment
Advanced ovarian cancer or other solid tumors
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04991480
Treatment
Advanced solid tumors
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Advanced solid tumors
CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations
Clinicaltrials.gov identifier:
NCT04586335
Treatment
Advanced solid tumors
Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
Clinicaltrials.gov identifier:
NCT03685331
Treatment
Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations
Clinicaltrials.gov identifier:
NCT03344965
Treatment
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
Clinicaltrials.gov identifier:
NCT03990896
Treatment
RADCOMP: A Study at the Heart of Breast Cancer Treatment
Clinicaltrials.gov identifier:
NCT02603341
Treatment
If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov
Sponsored By:
